The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
IL-6 and NF-IL6 in acute-phase response and viral infection
Abstract
NF-IL6 was originally identified as a DNA-binding protein responsible for IL-1-stimulated IL-6 induction. Direct cloning of NF-IL6 revealed its homology with C/EBP. C/EBP is expressed in liver and adipose tissues and is supposed to regulate several hepatocyte- and adipocyte-specific genes. In contrast, NF-IL6 is suppressed in normal tissues, but is rapidly and drastically induced by LPS or inflammatory cytokines such as IL-1, TNF, and IL-6. NF-IL6 can also bind to the regulatory region of various genes including IL-8, G-CSF, IL-1 and immunoglobulin genes. Furthermore, NF-IL6 is shown to be identical to IL-6DBP, a DNA-binding protein responsible for IL-6-mediated induction in acute-phase proteins, demonstrating that NF-IL6 is responsible for the genes regulated by IL-6. These results indicate that NF-IL6 may be a pleiotropic mediator of many inducible genes involved in acute, immune, and inflammatory responses, like NFkB. In this regard, it is noteworthy that both an NF-IL6 binding site and an NFkB binding site are present in the inducible genes such as IL-6, IL-8, and several acute-phase genes. On the other hand, accumulating evidence has revealed that overproduction of IL-6 may be responsible for the pathogenesis and/or several symptoms of a variety of diseases, including autoimmune diseases, malignancies, and viral diseases. At present, the molecular mechanisms of abnormal expression of the IL-6 gene are not known. Recently it has become evident that interplays between vira…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The cis-regulatory elements of the 5′-flanking region of the human IL-6 gene have binding motifs for NF-κB, nuclear factor IL6 (NF-IL6, also known as CAAT/enhancer-binding protein β), activator protein 1 (AP1), specificity protein 1 (SP1), and interferon regulatory factor 1 (IRF1) (Akira and Kishimoto, 1992”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Akira and Kishimoto, 1992
Citations
Cites
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Self-citationHirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F., Shimizu, M., Murashima, A., Tsunasawa, S., & Sakiyama, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.228 · Cited by 351
Research works printed but not linked: 93
- 10.1096/fasebj.4.11.2199284 · DOI
- 10.1002/j.1460-2075.1990.tb08316.x · DOI
- Amadori A., 1989, HIV‐specific B cell activation: a major constituent of spontaneous B cell activation during HIV‐infection, J. Immunol., 143, 2146, 10.4049/jimmunol.143.7.2146 · DOI
- 10.1016/0014-5793(87)80344-7 · DOI
- Asano S., 1990, In vivo effects of recombinant human interieukin‐6 in primates; Stimulated production of platelets, Blood, 75, 1602, 10.1182/blood.V75.8.1602.1602 · DOI
- 10.1093/nar/19.6.1213 · DOI
- Baumann H., 1989, Hepatocyte‐stimulating factor III shares structural and functional indentity with leukemia‐inhibitory factor, J. Immunol., 143, 1163, 10.4049/jimmunol.143.4.1163 · DOI
- 10.1016/0167-5699(90)90139-Z · DOI
- 10.1182/blood.V76.11.2303.2303 · DOI
- 10.1002/j.1460-2075.1990.tb07614.x · DOI
- Breen E. C., 1990, Infection with HIV is associated with elevated lL‐6 levels and production, J. Immunol., 144, 480, 10.4049/jimmunol.144.2.480 · DOI
- 10.1128/MCB.10.12.6642 · DOI
- 10.1101/gad.3.9.1323 · DOI
- 10.1038/345084a0 · DOI
- 10.1073/pnas.81.8.2313 · DOI
- 10.1101/gad.3.9.1314 · DOI
- 10.1016/0165-5728(89)90029-5 · DOI
- 10.1073/pnas.84.20.7251 · DOI
- 10.1111/j.1749-6632.1989.tb23998.x · DOI
- 10.1126/science.1542794 · DOI
- 10.1002/j.1460-2075.1987.tb02742.x · DOI
- 10.1002/eji.1830180510 · DOI
- Gohsh S., 1990, Cloning of the p50 DNA subunit of the transcription factor NF‐kB. p50 reveals remarkable homology at the amino terminal end to the oncogene v‐rel, Cell, 62, 1019
- 10.1073/pnas.86.16.6367 · DOI
- 10.1073/pnas.87.6.2364 · DOI
- 10.1016/0167-5699(90)90173-7 · DOI
- 10.1002/eji.1830181122 · DOI · Paper page
- 10.1038/324073a0 · DOI · Paper page
- Horii Y., 1989, Involvement ofinterleukin‐6 in mesangial proliferative glomerulonephritis, J. Immunol., 143, 3949, 10.4049/jimmunol.143.12.3949 · DOI
- Isshiki H., 1991, Reciprocal expression of NF‐IL6 and C/EBP in hepatocytes: Possible involvement of NF‐IL6 in acute phase protein gene expression, New Biologist, 3, 63
- 10.1128/MCB.10.6.2757 · DOI
- 10.1093/nar/17.22.9425 · DOI
- 10.1073/pnas.87.1.251 · DOI
- 10.1016/S0021-9258(18)98648-5 · DOI
- 10.1016/0092-8674(90)90275-J · DOI
- 10.1146/annurev.iy.06.040188.002413 · DOI
- Koj A., 1985, The Acute‐Phase Response to Injury and Infection., Elsevier, 10, 139
- 10.1111/j.1749-6632.1982.tb22124.x · DOI
- 10.1101/gad.2.7.786 · DOI
- 10.1126/science.3289117 · DOI · Paper page
- 10.1126/science.2494700 · DOI
- LeClair K. P., 1992, Using in‐vitro phosphorylated NF‐kB p50 protein to study its interactions with other proteins, J. Celt. Biochem. Keystone Symposia on Molecular & Cellular Biology, 87
- 10.1016/0092-8674(89)90833-7 · DOI
- Li X., 1991, Expression of rat serum amyloid Al gene involves both C/EBP‐like and NF kB‐like transcription factors, J. Biol. Chem., 266, 15192, 10.1016/S0021-9258(18)98603-5 · DOI
- 10.1128/MCB.10.12.6624 · DOI
- 10.1128/MCB.10.5.2327 · DOI
- Lu Y. M., 1989, Effects of long terminal repeat mutations on human immunodeficeintly virus type replication, J. Virol., 63, 4115, 10.1128/jvi.63.9.4115-4119.1989 · DOI
- 10.1073/pnas.87.4.1491 · DOI
- Mahe Y, 1991, Hepatitis B virus X protein transactivates human interIeukin‐8 gene through acting on nuclear factor kB and CCA AT/ enhancer‐binding protein‐like elements, J. Biol. Chem., 266, 13759, 10.1016/S0021-9258(18)92765-1 · DOI
- 10.1002/j.1460-2075.1990.tb08131.x · DOI
- Mann E. A., 1991, Identification of sequences mediating interleukm‐6 induction of a rat T kininogen gene, J. Biol. Chem., 266, 16931, 10.1016/S0021-9258(18)55392-8 · DOI
- 10.1126/science.2184517 · DOI
- Metz R., 1991, The helix‐loop‐helix protein rE12 and the C/EBP‐related factor rNFIL‐6 bind to neighboring sites within the c‐fos serum response element, Oncogene, 6, 2165
- 10.1073/pnas.87.11.4068 · DOI
- 10.1126/science.1542793 · DOI
- Morrone G., 1988, Recombinant interleukine 6 regulates the transcriptional activation of a set of human acute phase genes, J. Biot. Chem., 263, 12554, 10.1016/S0021-9258(18)37790-1 · DOI
- 10.1002/j.1460-2075.1989.tb08553.x · DOI
- Mukaida N., 1990, Cooperative interaction of NF‐kB‐and C/EBP‐like factor binding elements in activating the interleukin‐8 gene by proinflammatory cytokines, J. Biot. Chem., 265, 21128, 10.1016/S0021-9258(17)45336-1 · DOI
- 10.1126/science.1542792 · DOI
- 10.1016/S0006-291X(88)81305-6 · DOI · Paper page
- Nakajima K., 1989, Induction of IL‐6 (B cell stimulatory factor2/IFN/β2) production by HIV, J. Immunol, 142, 531, 10.4049/jimmunol.142.2.531 · DOI
- Natsuka S., 1992, Macrophage differentiation specific expression of NF‐IL6, a transcription factor for IL‐6, Blood, 19, 460, 10.1182/blood.V79.2.460.460 · DOI
- 10.1016/0014-5793(91)81103-F · DOI
- 10.1016/S0140-6736(87)91413-9 · DOI
- 10.1016/0090-1229(89)90147-5 · DOI
- 10.1128/MCB.10.5.2002 · DOI
- 10.1016/0092-8674(91)90320-X · DOI
- 10.1002/j.1460-2075.1989.tb03485.x · DOI
- Oyaizu N., 1991, Human immunodeficiency virus type 1 envelope glycoproteins gp120 and gpl60 induce inlerleukin‐6 production in CD4+T‐cell clones, J. Virol., 65, 6277, 10.1128/jvi.65.11.6277-6282.1991 · DOI
- 10.1073/pnas.86.19.7532 · DOI
- 10.1073/pnas.86.21.8202 · DOI
- 10.1016/0092-8674(90)90459-R · DOI
- 10.1128/MCB.10.11.5736 · DOI
- 10.1128/MCB.9.12.5537 · DOI
- 10.1038/346668a0 · DOI
- 10.1172/JCI115566 · DOI
- 10.1073/pnas.88.17.7605 · DOI
- 10.1016/0092-8674(86)90341-7 · DOI
- 10.1128/MCB.10.2.561 · DOI · Paper page
- 10.1016/S0092-8674(88)80034-5 · DOI
- 10.1073/pnas.87.7.2838 · DOI
- Spergel J. M., 1992, NF‐IL6, a member of the C/EBP family, regulates E1A‐responsive promoters in the absence of E1A, J. Virol, 10.1128/jvi.66.2.1021-1030.1992 · DOI
- 10.1073/pnas.86.19.7547 · DOI · Paper page
- Tanabe O., 1988, Genomic structure of the murine IL‐6 gene: High degree conservation of potential regulatory sequences between mouse and human, J. Immunol., 141, 3875, 10.4049/jimmunol.141.11.3875 · DOI
- 10.1002/eji.1830180202 · DOI
- 10.1038/335606a0 · DOI
- 10.1038/336684a0 · DOI
- 10.1128/MCB.10.12.6181 · DOI
- 10.1128/MCB.10.8.3965 · DOI
- 10.1002/j.1460-2075.1987.tb02598.x · DOI
- Yoshizaki K., 1989, Pathological significance of B cell stimulatory factor 2 (BSF‐2/IL‐6) in Castleman's disease, Blood, 4, 1360
- 10.1073/pnas.83.24.9739 · DOI
- 10.1128/MCB.10.7.3818 · DOI
Cited by
Sorted by citations
The anti-inflammatory effect of exercise
Petersen, A. M. W., & Pedersen, B. K. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00164.2004 · Cited by 3,100
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Pedersen, B. K., & Febbraio, M. A. (2008) · Physiological Reviews · doi:10.1152/physrev.90100.2007 · Cited by 2,388
Particulate air pollution and acute health effects
Seaton, A., Godden, D., MacNee, W., & Donaldson, K. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90173-6 · Cited by 2,138
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Self-citationYamamoto, K., Arakawa, T., Ueda, N., & Yamamoto, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.52.31315 · Cited by 647
Lin, Z.-Q., Kondo, T., Ishida, Y., Takayasu, T., & Mukaida, N. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0802397 · Cited by 585
Severe liver degeneration and lack of NF-κ B activation in NEMO/IKKγ-deficient mice
Rudolph, D., Yeh, W.-C., Wakeham, A., Rudolph, B., Nallainathan, D., Potter, J., Elia, A. J., & Mak, T. W. (2000) · Genes & Development · doi:10.1101/gad.14.7.854 · Cited by 479
Historical overview of the interleukin-6 family cytokine
Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190347 · Cited by 360
Self-citationKoenig, H. G., Cohen, H. J., George, L. K., Hays, J. C., Larson, D. B., & Blazer, D. G. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/40nf-q9y2-0gg7-4wh6 · Cited by 251
Regulation of IL-6 in Immunity and Diseases
Tanaka, T., Narazaki, M., Masuda, K., & Kishimoto, T. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-024-0921-5_4 · Cited by 235
Self-citationGoya, K., Sumitani, S., Xu, X., Kitamura, T., Yamamoto, H., Kurebayashi, S., Saito, H., Kouhara, H., Kasayama, S., & Kawase, I. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000118682.58708.78 · Cited by 174
Zhang, X., Wu, K., Wang, D., Yue, X., Song, D., Zhu, Y., & Wu, J. (2007) · Virology · doi:10.1016/j.virol.2007.04.009 · Cited by 141
“…transcription factors with known consensus sequences in the IL-6 promoter region, including IRF-1 (−267 to −254), AP-1 (−283 to −277), C/EBP (−158 to −145 and −87 to −76), Sp1 (−123 to −119 and −108 to −104), and NF-κB (−75 to −63) binding sites (Akira and Kishimoto, 1992; Yan et al., 1995).”
BackgroundIL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Self-citationMüller, C., Kowenz‐Leutz, E., Grieser‐Ade, S., Graf, T., & Leutz, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00303.x · Cited by 91
Separation of C/EBPα-mediated proliferation arrest and differentiation pathways
Müller, C., Alunni-Fabbroni, M., Kowenz-Leutz, E., Mo, X., Tommasino, M., & Leutz, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7276 · Cited by 61
Williamson, E. A., Xu, H. N., Gombart, A. F., Verbeek, W., Chumakov, A. M., Friedman, A. D., & Koeffler, H. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.14796 · Cited by 50
Kwon, Y. B., Lee, Y.-S., Sohn, K.-C., Piao, Y.-J., Back, S. J., Seo, Y.-J., Suhr, K.-B., Park, J.-K., Kim, C. D., & Lee, J.-H. (2007) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2007.01.007 · Cited by 15
Metadata
- Authors
- Akira, S., & Kishimoto†, T.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 1992-06
- Volume
- 127
- Issue
- 1
- Pages
- 25-50
- ISSN
- 0105-2896
- 1600-065X
- Cited by
- 411
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review